Vifor Pharma (GNHAF) Stock Price, News & Analysis

Company Overview

Vifor Pharma AG is a Switzerland‐headquartered pharmaceutical company specializing in treatments for iron deficiency, nephrology and related therapeutic areas. Established in 2017 following the separation of Galenica into two standalone entities, Vifor Pharma traces its roots to the 19th century and has since grown into a leader in iron therapy and kidney disease management. The company develops, manufactures and commercializes innovative prescription medicines and medical devices, working closely with healthcare professionals to address unmet needs in patient care.

The company’s product portfolio includes intravenous iron therapies such as Venofer (iron sucrose) and Ferinject (ferric carboxymaltose), as well as phosphate binders like Velphoro (sucroferric oxyhydroxide). In 2016, Vifor Pharma expanded its nephrology pipeline through the acquisition of Relypsa, gaining Veltassa (patiromer) for the treatment of hyperkalemia. Ongoing research and development efforts focus on next‐generation treatments in iron deficiency, chronic kidney disease and supportive care for patients with complex comorbidities.

Vifor Pharma operates in over 100 countries, leveraging a global network of subsidiaries, partnerships and distribution channels. The company maintains manufacturing facilities in Europe and North America and collaborates with strategic partners including leading dialysis providers. Its commercial teams serve key markets across Europe, the United States, Asia Pacific and Latin America, adapting product access programs to local healthcare systems and reimbursement environments.

Governed by an experienced international leadership team based in St. Gallen, Switzerland, Vifor Pharma’s management combines deep expertise in pharmaceutical development, marketing and regulatory affairs. The company is listed on the SIX Swiss Exchange under the ticker VIFN and trades on the OTC market in the United States under the symbol GNHAF, reflecting its commitment to transparency and engagement with the global investment community.

Key Stats

• Today's Range: $181.25 to $181.25
• 50-Day Range: $181.25 to $181.25
• 52-Week Range: $174.25 to $183.50
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNHAF Stock Analysis - Frequently Asked Questions

How have GNHAF shares performed this year?

Vifor Pharma's stock was trading at $181.25 at the beginning of 2025. Since then, GNHAF stock has increased by 0.0% and is now trading at $181.25.

How do I buy shares of Vifor Pharma?

Shares of GNHAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNHAF
• CIK: N/A
• Web: www.viforpharma.com
• Phone: (158) 851-8000
• Fax: N/A
• Employees: 2,200
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A